证券代码： 301130 证券简称：西点药业 吉林省西点药业科技发展股份有限公司 投资者关系活动记录表 编号：20240529 投资者关系活动 □特定对象调研 □ 分析师会议 类别 □ 媒体采访 √ 业绩说明会 □ 新闻发布会 □ 路演活动 □ 现场参观 □ 其他 （请文字说明其他活动内容） 参与单位名称及 投资者网上提问 人员姓名 时间 2024年5 月29日 (周三) 下午 15:00~16:30 地点 公司通过全景网“投资者关系互动平台”（https://ir.p5w.net） 采用网络远程的方式召开业绩说明会 上市公司接待人 1、董事长、总经理 张俊 员姓名 2、董事、副总经理 石英秀 3、副总经理、董事会秘书 张银姬 4、公司财务总监 孟思 5、公司独立董事 卢相君 6、保荐代表人 赵琼琳 投资者提出的问题及公司回复情况 公司就投资者在本次说明会中提出的问题进行了回复： ...

吉林省西点药业科技发展股份有限公司 关于使用部分闲置募集资金进行现金管理及 证券代码：301130 证券简称：西点药业 公告编号：2024-058 近日，公司使用部分闲置募集资金进行现金管理及使用部分闲置自有资金进 行委托理财，现就具体情况公告如下： 签约机构 产品名称 产品类型 金额 （万 元） 产品起 息日 产品到 期日 预期年化 收益率 资金 来源 中国建设银行 股份有限公司 长春南亚泰大 街支行 中国建设银行 单位人民币定 制型结构性存 款 保本浮动收 益型结构性 存款 5,000.0 0 2024/0 5/22 2024/08 /22 1.05%- 2.2% 募集资金 中信建投证券 股份有限公司 百瑞至诚-信投 睿享 10 号集合 资金信托计划 非保本浮动 收益型 2,000.0 0 2024/0 5/14 预计 2024/08 /14 浮动收益 自有资金 一、本次现金管理和委托理财产品的基本情况 二、审批程序 《关于使用部分闲置募集资金进行现金管理及使用部分闲置自有资金进行 现金管理和委托理财的议案》已经第八届董事会第四次会议、第八届监事会第四 次会议审议通过，公司监事会和保荐机构均发表了明确同意 ...

吉林省西点药业科技发展股份有限公司（以下简称"公司"）已于 2024 年 4 月 23 日巨潮资讯网 (www.cninfo.com.cn)上披露了《2023 年年度报告》及《2023 年年度报告摘要》。 为进一步加强与投资者的互动交流，公司将参加由吉林省证券业协会、深圳 市全景网络有限公司共同举办的"2024 年吉林辖区上市公司网上集体业绩说明 会"，现将有关事项公告如下： 本次集体业绩说明会将通过深圳市全景网络有限公司提供的互联网平台举行， 投资者可以登陆"全景网"投资者关系互动平台"（http://ir.p5w.net）参与公 司业绩说明会,时间为 2024 年 5 月 29 日（星期三）15:00 至 16:30。 证券代码：301130 证券简称：西点药业 公告编号：2024-057 吉林省西点药业科技发展股份有限公司 关于参加网上集体业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 吉林省西点药业科技发展股份有限公司董事会 2024 年 5 月 20 日 届时公司董事长、总经理张俊先生，公司董事、副总经理石英秀先生，公司 副总经理、 ...

证券代码：301130 证券简称：西点药业 公告编号：2024-056 吉林省西点药业科技发展股份有限公司 关于使用部分闲置募集资金进行现金管理到期赎回 并继续进行现金管理的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 吉林省西点药业科技发展股份有限公司（以下简称"公司"）于 2024 年 2 月 1 日召开第八届董事会第四次会议、第八届监事会第四次会议，分别审议通过了 《关于使用部分闲置募集资金进行现金管理及使用部分闲置自有资金进行现金 管理和委托理财的议案》，同意公司在确保募集资金投资项目建设正常进行和资 金安全的前提下，使用额度不超过人民币 2.0 亿元的部分闲置募集资金（含超募 资金）进行现金管理，公司及全资子公司在确保不影响公司日常经营的前提下， 使用额度不超过人民币 1.5 亿元的部分闲置自有资金进行现金管理和委托理财， 用于购买安全性高、流动性好、期限不超过 12 个月的短期投资理财产品。使用 期限自董事会审议通过之日起 12 个月内有效。在上述额度和期限内，资金可循 环滚动使用。具体内容详见公司在巨潮资讯网上披露的《关于使用部分闲置 ...

证券代码：301130 证券简称：西点药业 公告编号：2024-055 吉林省西点药业科技发展股份有限公司 关于使用部分闲置募集资金进行现金管理及部分闲置自有资金 进行委托理财部分到期赎回并继续进行现金管理和委托理财的 进展公告 | 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 | | --- | | 假记载、误导性陈述或重大遗漏。 | 吉林省西点药业科技发展股份有限公司（以下简称"公司"）于 2024 年 2 月 1 日召开第八届董事会第四次会议、第八届监事会第四次会议，分别审议通过了 《关于使用部分闲置募集资金进行现金管理及使用部分闲置自有资金进行现金 管理和委托理财的议案》，同意公司在确保募集资金投资项目建设正常进行和资 金安全的前提下，使用额度不超过人民币 2.0 亿元的部分闲置募集资金（含超募 资金）进行现金管理，公司及全资子公司在确保不影响公司日常经营的前提下， 使用额度不超过人民币 1.5 亿元的部分闲置自有资金进行现金管理和委托理财， 用于购买安全性高、流动性好、期限不超过 12 个月的短期投资理财产品。使用 期限自董事会审议通过之日起 12 个月内有效。在上述额度和期限内 ...

吉林省西点药业科技发展股份有限公司 关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 1、吉林省西点药业科技发展股份有限公司（以下简称"公司"）拟使用自 有资金不低于人民币 5,000 万元（含）且不超过人民币 10,000 万元（含）以集 中竞价交易方式回购公司已发行的人民币普通股（A 股）股票，用于注销并减少 注册资本，回购价格不超过人民币 30.00 元/股（含），回购期限为自股东大会 审议通过本次回购股份方案之日起 12 个月内，具体回购股份的数量以回购期限 届满时实际回购的股份数量为准。具体内容详见公司于 2024 年 2 月 28 日在巨潮 资讯网（www.cninfo.com.cn）披露的《回购报告书》。 2、公司已于 2024 年 2 月 4 日召开第八届董事会第五次会议、第八届监事会 第五次会议，并于 2024 年 2 月 23 日召开 2024 年第一次临时股东大会，分别审 议通过了《关于回购公司股份方案的议案》。 根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 9 号——回购股 ...

吉林省西点药业科技发展股份有限公司 2023 年度定期现场检查报告 | 保荐机构名称：海通证券股份有限公司 被保荐公司简称：西点药业 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 保荐代表人姓名：赵琼琳 联系电话：021-23180000 | | | | | | | | | | 保荐代表人姓名：黄蕾 联系电话：021-23180000 | | | | | | | | | | 现场检查人员姓名：赵琼琳、陈艺伟 | | | | | | | | | | 现场检查对应期间：2023 年度 | | | | | | | | | | 现场检查时间：2024 年 4 10 日-2024 年 4 | 月 | 月 | 12 | 日 | | | | | | 一、现场检查事项 | | | | | | | 现场检查意见 | | | （一）公司治理 | | | | | | 是 | 否 | 不适用 | | 现场检查手段：1、查阅公司章程、各项规章制度；2、查阅公司历次董事会、监事会、 | | | | | | | | | | 股东大会文 ...

Financial Performance - The company's revenue for Q1 2024 was ¥66,705,459.25, representing a 20.32% increase compared to ¥55,440,064.10 in the same period last year[5] - Net profit attributable to shareholders for Q1 2024 was ¥14,042,843.67, a 46.66% increase from ¥9,575,298.60 year-over-year[5] - The net profit after deducting non-recurring gains and losses was ¥12,061,082.58, showing a significant increase of 90.22% from ¥6,340,660.01 in the previous year[5] - Basic and diluted earnings per share for Q1 2024 were both ¥0.1738, reflecting a 46.67% increase compared to ¥0.1185 in the previous year[5] - The operating profit for the first quarter was CNY 16,305,235.17, up from CNY 11,043,044.54, indicating a growth of 47.5% year-over-year[24] - The total comprehensive income for the first quarter was CNY 14,042,843.67, compared to CNY 9,575,298.60 in the previous year, reflecting a 46.5% increase[25] Cash Flow - The net cash flow from operating activities reached ¥7,445,732.65, a remarkable turnaround from a negative cash flow of ¥632,674.43 in the same quarter last year, marking a 1,276.87% improvement[5] - Cash flow from operating activities generated a net inflow of CNY 7,445,732.65, a significant improvement from a net outflow of CNY -632,674.43 in the previous year[26] - Cash inflow from investment activities totaled CNY 238,619,544.48, down from CNY 404,918,801.08 in the same period last year[26] - Cash outflow for investment activities was CNY 232,351,716.60, compared to CNY 396,288,655.62 in the previous year[27] - The net cash flow from financing activities was CNY -61,366,187.07, indicating cash outflows related to financing[27] Assets and Liabilities - Total assets at the end of Q1 2024 were ¥1,002,981,793.10, a decrease of 6.02% from ¥1,067,195,971.50 at the end of the previous year[5] - The total liabilities decreased to RMB 67,390,209.11 from RMB 84,332,557.25, reflecting a reduction of 20.1%[22] - The company’s fixed assets increased to RMB 299,987,910.49 from RMB 236,483,272.86, an increase of 26.8%[21] - Cash and cash equivalents decreased to RMB 286,718,076.27 from RMB 334,370,419.58 at the beginning of the period, a decline of 14.2%[20] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 8,195[11] - The largest shareholder, Zhang Jun, holds 24.29% of the shares, totaling 19,627,034 shares[11] - The total number of restricted shares at the beginning of the period was 22,775,809, with no shares released or added during the reporting period[14] - The top ten shareholders hold a total of 22,775,809 shares, with the largest shareholder holding 19,627,034 shares[14] - The company has a significant number of shares held by major shareholders, with the largest shareholder, Zhang Jun, holding 19,627,034 shares, representing a substantial portion of the total[14] Strategic Developments - The company plans to establish a wholly-owned subsidiary, Jilin Xinqing Pharmaceutical Technology Co., Ltd., with an investment of RMB 10 million, which has completed the necessary registration procedures[15] - The company received a Supplementary Application Approval Notice from the National Medical Products Administration for its injectable Rosuvastatin Acetate[16] - The company is focused on expanding its market presence through new product approvals and subsidiary establishment[16] - The company is actively pursuing new product development and regulatory approvals to enhance its product portfolio[16] - The company has established a strategic relationship with several investment firms, indicating potential for future capital influx[12] Other Information - The company appointed Ms. Zhang Yinjie as the Vice General Manager and Secretary of the Board, effective from February 1, 2024[15] - The company has not reported any changes in the number of shares lent or returned in the securities lending business during the reporting period[12] - The company repurchased a total of 2,681,558 shares, representing 3.32% of the total share capital, with a total transaction amount of RMB 61,304,621.75[18] - The first quarter report was not audited, as indicated by the company[28]

吉林省西点药业科技发展股份有限公司 审计报告 大华审字[2024]0011006259 号 大 华 会 计 师 事 务 所 （ 特 殊 普 通 合 伙 ） Da Hua Certified Public Accountants（Special General Partnership） 吉林省西点药业科技发展股份有限公司 审计报告及财务报表 （2023 年 1 月 1 日至 2023 年 12 月 31 日止） | | 目 | 录 | 页 次 | | --- | --- | --- | --- | | 一、 | 审计报告 | | 1-6 | | 二、 | 已审财务报表 | | | | | 合并资产负债表 | | 1-2 | | | 合并利润表 | | 3 | | | 合并现金流量表 | | 4 | | | 合并股东权益变动表 | | 5-6 | | | 母公司资产负债表 | | 7-8 | | | 母公司利润表 | | 9 | | | 母公司现金流量表 | | 10 | | | 母公司股东权益变动表 | | 11-12 | | | 财务报表附注 | | 1-73 | 一、审计意见 我们审计了吉林省西点药业科技发 ...

Financial Performance - The company's operating revenue for 2023 was CNY 225,491,234.57, a decrease of 11.73% compared to CNY 255,467,987.43 in 2022[21]. - Net profit attributable to shareholders increased by 24.01% to CNY 50,502,418.80 in 2023, up from CNY 40,723,025.38 in 2022[21]. - The net profit after deducting non-recurring gains and losses was CNY 28,361,905.28, down 15.67% from CNY 33,633,860.81 in 2022[21]. - The total assets at the end of 2023 reached CNY 1,067,195,971.50, reflecting a growth of 4.94% from CNY 1,017,003,454.64 at the end of 2022[21]. - The basic earnings per share increased by 18.84% to CNY 0.6250 in 2023, compared to CNY 0.5259 in 2022[21]. - The company's total revenue for 2023 was ¥225,491,234.57, representing a year-over-year decrease of 11.73%[58]. - The net profit attributable to shareholders for 2023 was ¥50,502,418.80, showing a year-over-year increase of 24.01%[58]. - The main pharmaceutical business contributed ¥225,141,192.09, accounting for 99.84% of total revenue, with a year-on-year decline of 11.85%[82]. - The revenue from the compound ferrous sulfate folic acid tablets was ¥116,064,612.30, representing 51.47% of total revenue, down 8.93% from the previous year[82]. Dividend Policy - The company plans to distribute a cash dividend of 2.60 RMB per 10 shares (including tax) to all shareholders[3]. - The total distributable profit for the company is 375,727,232.01 RMB, with cash dividends accounting for 100% of the profit distribution[188]. - The company has a stable profit distribution policy, prioritizing cash dividends while considering sustainable development[187]. - The company is in a mature development stage and aims to maintain a minimum of 40% cash dividend ratio during profit distribution[189]. - The company has no plans for stock dividends or bonus shares in the current profit distribution[190]. Market Position and Strategy - The company is positioned in the pharmaceutical manufacturing sector, focusing on the research, development, production, and sales of chemical drugs[31]. - The company has a focus on developing new products and technologies in the pharmaceutical sector[3]. - The company aims to become a competitive player in the domestic blood supplement and mental disorder medication markets, leveraging its integrated advantages in "raw materials + formulations"[50]. - The company is actively involved in the transformation and upgrading of the pharmaceutical industry, ensuring the safety and quality of drug operations and usage[49]. - The company is focused on ethical standards in scientific research, aligning with new regulations that promote comprehensive oversight in the field[49]. Research and Development - The company is focused on research and development, collaborating with academic institutions to accelerate product pipeline development[53]. - The company has 22 registered formulations and 16 active pharmaceutical ingredient (API) registrations, focusing on areas such as anemia treatment and psychiatric disorders[51]. - The company is actively developing new products, including protein succinate iron and risperidone orally disintegrating tablets, which are currently in the review stage[59]. - The company has initiated two new drug research projects based on the efficacy of Rhizoma Alismatis in treating complications related to diabetes and lymphatic obstruction[70]. - The company is committed to continuous R&D investment to create differentiated barriers and enhance its ability to withstand market risks[76]. Compliance and Governance - The company emphasizes compliance with new regulations and standards in the pharmaceutical industry, which are expected to enhance quality management and oversight throughout the drug lifecycle[48]. - The company has established a robust internal control system to enhance governance and ensure compliance with relevant laws and regulations[143]. - The board of directors consists of 9 members, including 3 independent directors, ensuring compliance with governance standards and enhancing decision-making processes[145]. - The company has a supervisory board consisting of 5 members, including 2 employee supervisors, complying with legal requirements[146]. - The company is focused on maintaining compliance and transparency in its governance practices[165]. Risk Management - The company emphasizes potential risks including policy risks from pharmaceutical system reforms and fluctuations in raw material prices[3]. - The company is facing policy risks due to ongoing medical system reforms, which may increase operational costs and alter business models if not adapted timely[135]. - Fluctuations in raw material prices pose risks to the company's profit margins, and it is focusing on R&D of raw materials to control costs[138]. - The company adopts a cautious approach to drug development, prioritizing projects with thorough market research to mitigate risks associated with high costs and low success rates[139]. Environmental Responsibility - The company has highlighted its commitment to environmental protection and social responsibility in its annual report[5]. - The company must comply with multiple environmental protection laws and standards, including the Water Pollution Prevention and Control Law and the Air Pollution Prevention and Control Standards[200]. - The company generates pollutants such as waste gas, wastewater, noise, and solid waste during its production operations[200]. - The company adheres to specific guidelines for self-monitoring and pollution control in the pharmaceutical industry[200]. Human Resources - The company has a total of 269 employees, with 118 in production, 70 in sales, 49 in technical roles, 10 in finance, 22 in administration[180]. - The company has conducted extensive training programs for employees, covering various aspects of quality management and compliance with GMP regulations[183][184]. - The number of R&D personnel decreased by 2.00% to 49 in 2023, with their proportion of total staff remaining relatively stable at 18.22%[97]. Financial Management - The company reported a significant increase in cash and cash equivalents, rising to 334,370,419.58, which is 31.33% of total assets, up from 19.94% at the beginning of the year[103]. - The company has a cash management balance of RMB 120 million, with RMB 116.30 million held in a special account for raised funds[117]. - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to 2.2854 million CNY[167]. - The company is actively involved in the management of its remuneration policies through a dedicated compensation and assessment committee[166]. Corporate Changes - The company held a shareholder meeting on August 3, 2023, to elect a new board of directors and supervisory board[156]. - Several directors, including Ding Shiguo, Wang Baozhong, and Liu Yanbin, completed their terms and left their positions on August 3, 2023[157]. - The company appointed new members to the eighth board of directors and supervisory board following the recent elections[156]. - The financial director Meng Si was appointed on August 3, 2023, indicating a leadership change in the financial management team[162][163].